Role of Platelet Rich Plasma Therapy on Rotator Cuff Disease

Abstract

Rotator cuff tendinopathy (RCT) and rotator cuff diseases (RCDs) are leading cause of shoulder pain and a significant source of disability and loss of work (Kuijpers et al., 2006, Rha et al., 2013 and Whittle & Buchbinder, 2015). It is a common disorder; approximately 16% of the general population is believed to have RCD at any given time (Erstad, 2008). Its prevalence increases substantial with age and with occupations involving overhead activities. They are affecting more than 50% of population above 60 years (Seitz et al., 2011). In spite of the long standing history and many studies and reviews found in literature concerning RCDs and mechanism of development of tendon tear, the pathophysiology of rotator cuff tendon diseases is still a controversial topic and hasn’t been fully understood (Rha et al., 2013). The biochemical and molecular events leading to RCD and tear have not yet been defined and still a matter of debate (Beasley et al., 2000; Dean et al., 2012 and Petterson et al., 2017).